Endocrinology 

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Articles

The FDA's ODD award is based on the positive findings from the phase 2 TouCAHn trial, which also support Crinetics' robust phase 3 pivotal clinical trial program for the novel agent. 

Atumelnant for Congenital Adrenal Hyperplasia Agent Granted FDA Orphan Drug Designation 

Your daily dose of the clinical news you may have missed.

New Data Highlight Significant Challenges to Managing CAH: Daily Dose

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

ENDO 2025: Most Patients With Classic Congenital Adrenal Hyperplasia Experience High Glucocorticoid Exposure or Suboptimal Control

Lundbeck announced the designation today and said it is expanding an ongoing phase I/II clinical open label trial of the investigational mAb in adults with classic CAH. 

FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia 

Slideshows

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Adrenal Disorders